Catalio Capital Logo

A multi-strategy investment firm focused on breakthrough biomedical technology companies worldwide
learn more

Private Equity Strategy
Our flagship private equity strategy invests in privately held breakthrough biomedical technology companies at all stages, from seed to crossover

Private Credit Strategy
Our structured opportunities strategy provides senior-secured financing to breakthrough biomedical technology companies

Public Equities Strategy
Our public equities strategy is a long bias, fundamental, bottoms-up equity long/short strategy investing in global healthcare equities across sectors: innovative drugs, devices, diagnostics and data.

Co-Investment Strategy
Our co-investment vehicles provide Catalio Limited Partners with direct access to our best deals
Private Equity
learn more
PRivate Credit
learn more
Public Equities
learn more
Co-Investment
learn more

About Catalio

Catalio was founded in 2020 by George Petrocheilos and R. Jacob Vogelstein to invest in the next generation of category-defining life sciences companies around the globe.  Our mission is to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with the best management teams and financial syndicates.  To achieve this objective, we work with an elite group of the world’s best scientists, engineers and clinicians – the Catalio Venture Partners – to identify breakthrough biotechnologies; co-invest with top-tier funds; and recruit A-list talent from our collective networks.
learn more

Our Portfolio

We focus on biomedical technology companies developing next-generation drugs, devices and diagnostics, data, tools, and healthcare services and work closely with each portfolio company to build and grow the business from inception to exit.
learn more

OUR TEAM

The Catalio team comprises a unique combination of investment professionals and world-renowned, serial scientist-entrepreneurs.  Together, we have a proven track record in starting up and spinning out category-defining businesses in the life sciences.
learn more

CONTACT

Our team works 24/7 in support of our partners, investors, and portfolio companies, so we are always happy to hear from you.
reach out now

RECENT NEWS

Congrats to our portfolio company ⁦@CambrianBio⁩ on their $100M Series C financing! Delighted to continue partnering with ⁦@C_Angermayer⁩, ⁦@JamesPeyer⁩, ⁦@brentlsaunders⁩ & their team in their quest to slow down human aging! https://t.co/kGUxldJdqy
RT @CatalioCapital: Today we are excited to announce the merger of our Healthcor Catalio SPAC ($HCAQ) with ⁦@Hyperfine⁩, founded by ⁦@JMRot…
The Pentagon Is Reportedly Auditing the U.S. Military's Own Pro-America Social Media Psyop
September 2022
Uber Says It Was Likely Hacked by Teenage Hacker Gang LAPSUS$
September 2022
NASA Wants Ideas for a New Lunar Lander
September 2022
See More Tweets